Lifecore Biomedical
LFCR
99 hedge funds and large institutions have $133M invested in Lifecore Biomedical in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 19 closing their positions.
178% more call options, than puts
Call options by funds: $408K | Put options by funds: $147K
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
19% more capital invested
Capital invested by funds: $112M → $133M (+$21M)
0.73% more ownership
Funds ownership: 67.01% → 67.75% (+0.73%)
6% less funds holding
Funds holding: 105 → 99 (-6)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
3C
325 Capital
New York
|
+$3.69M |
| 2 |
BlackRock
New York
|
+$684K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$600K |
| 4 |
Renaissance Technologies
New York
|
+$528K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Grizzlyrock Capital
Chicago,
Illinois
|
-$3.65M |
| 2 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
-$1.75M |
| 3 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$391K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$279K |
| 5 |
Goldman Sachs
New York
|
-$219K |
LFCR Hedge Fund Activity: Q2 2026 in Review
99 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q2 2026, worth a combined $133M — up 19% from $112M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LFCR and 15 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 35 added.
The largest buyer was 325 Capital, adding an estimated $3.69M. The largest seller was Grizzlyrock Capital, cutting an estimated $3.65M.
- 99 institutional investors held Lifecore Biomedical (LFCR) as of Q2 2026, down from 105 in Q1 2026.
- Funds reported $133M of Lifecore Biomedical stock for Q2 2026, up 19% quarter-over-quarter.
- 15 funds opened new Lifecore Biomedical positions in Q2 2026 and 19 closed out, a net change of -4 holders.
- The largest Lifecore Biomedical buyer in Q2 2026 was 325 Capital, an estimated $3.69M added.
- The largest Lifecore Biomedical seller in Q2 2026 was Grizzlyrock Capital, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2026.